FDA OKs new label expansions for Dupixent and Incyte's Monjuvi

Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...